Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 3/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 3/20 | 0.38 |
| ▸ | BCR | P11274 | 2/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.38 |
| ▸ | CRACR2A | Q9BSW2 | 2/20 | 0.38 |
| ▸ | WNT3A | P56704 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1408282 | 0.89 | KDR (0.47) | MCHR1KDRROCK2RORCABL1 | |
| SCHEMBL2202372 | 0.87 | KDR (0.47) | KDRMAPTTP53ROCK2MEN1 | |
| SCHEMBL2201467 | 0.87 | MCHR1 (0.43) | MCHR1KDRMAPTTP53ROCK2 | |
| SCHEMBL2203641 | 0.86 | RORC (0.51) | KDRMAPTTP53ROCK2MEN1 | |
| SCHEMBL1408415 | 0.84 | MAPT (0.43) | MAPTTP53ROCK2MEN1KMT2A | |
| SCHEMBL1408439 | 0.83 | ABL1 (0.55) | ABL1BCRMKNK1MKNK2 | |
| SCHEMBL1408584 | 0.83 | MAPT (0.46) | KDRMAPTTP53ROCK2MEN1 | |
| SCHEMBL1407936 | 0.81 | MAPT (0.52) | KDRMAPTTP53ROCK2MEN1 | |
| SCHEMBL1407961 | 0.81 | MAPT (0.48) | KDRMAPTTP53ROCK2MEN1 | |
| SCHEMBL2203087 | 0.79 | MKNK2 (0.50) | KDRMAPTTP53ROCK2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120184561-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-07-19 | — | — | US | claimed |
| US-8030311-B2 | Phenylacetamides suitable as protein kinase inhibitors | NOVARTIS AG (CH) | 2011-10-04 | — | — | US | claimed |
| EP-1874770-B1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-09 | — | — | EP | claimed |
| US-20080319005-A1 | Phenylacetamides Suitable as Protein Kinase Inhibitors | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | claimed |
| CN-101198607-A | Phenylacetamides suitable as protein kinase inhibitors | NOVARTIS AG (CH) | 2008-06-11 | — | — | CN | claimed |
| EP-1874770-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | Novartis Pharma AG (CH) | 2008-01-09 | — | — | EP | claimed |
| WO-2006108640-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | claimed |
| US-20120184561-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-07-19 | — | — | US | disclosed |
| US-8030311-B2 | Phenylacetamides suitable as protein kinase inhibitors | NOVARTIS AG (CH) | 2011-10-04 | — | — | US | disclosed |
| US-20080319005-A1 | Phenylacetamides Suitable as Protein Kinase Inhibitors | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184561-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | MAP3K10, MAP3K20, MAP3K9 | MCHR1 4261/4885KDR 1923/4885MAPT 2709/4885 |
| US-20080319005-A1 | Phenylacetamides Suitable as Protein Kinase Inhibitors | MAP3K20, MAP3K10, MAP3K9 | MCHR1 4136/4885KDR 1839/4885MAPT 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.